Clinical trials: Renal Cell Cancer Metastatic
Metastatic Clear Cell Renal Cell Carcinoma
CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk
The purpose of this study is to evaluate the safety and feasibility of a treatment holiday strategy directed by CD70-targeted immuno-PET/CT in patients with metastatic clear cell renal cell carcinoma (mccRCC).
- Trial name
- PERFUMER-70 (NCT07615348)
- Testing
- PD-1/PD-L1 ICI + VEGFR-TKI, Treatment pause
- Where
- 5 sites in China
- Volunteers
- 75 people
- Sponsor
- Jinling Hospital, China
Carcinoma, Renal Cell
Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging
The goal is to study the impact of functional MRI and CT evaluation of changes in tumor vessels induced by anti-angiogenic treatment in patients with metastatic RCC.
- Trial name
- REMISCAN (NCT00842790)
- Where
- France
- Volunteers
- 107 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Clear Cell Renal Cell Carcinoma
68Ga-NYM096/177Lu-NYM096 in Metastatic ccRCC
This is a single-center, phase I study. Patients with metastatic clear cell renal cell carcinoma will be recruited in this study to (Phase A) evaluate using 68Ga-NYM096 PET/CT and to (Phase B) treat with 177Lu-NYM096.
- Trial name
- NYCRRLT (NCT06649682)
- Testing
- 68Ga-NYM096 PET/CT and 177Lu-NYM096
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Advanced/Metastatic Clear Cell Renal Cell Carcinoma, Recurrence
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
This is a multi-center, open-label phase 1/2 trial evaluating the safety and efficacy of AB-2100 cell product. The study may enroll approximately 60 patients in phase 1 and approximately 70 patients in phase 2.
- Trial name
- NCT06245915
- Testing
- AB-2100
- Where
- 8 sites in United States
- Volunteers
- 37 people
- Sponsor
- Arsenal Biosciences, Inc.
Renal Cell Cancer, Kidney Cancer
Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)
The goal of this clinical research study is to find the highest tolerable dose of the combination of sunitinib and temsirolimus that can be given to patients with metastatic kidney cancer.
- Trial name
- NCT01122615
- Testing
- Sunitinib, Temsirolimus
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Kidney Cancer, Melanoma (Skin)
High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer or melanoma cells.
- Trial name
- NCT00003091
- Testing
- aldesleukin, recombinant interferon alfa
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Hoag Memorial Hospital Presbyterian
Carcinoma, Renal Cell, Neoplasm Metastasis
A Research Study for Patients With Metastatic Renal Cell Carcinoma
The purpose of this study is to evaluate the activity of FK228 in metastatic renal cell carcinoma (RCC) patients who have developed progressive disease (PD) following or during treatment with immunotherapy.
- Trial name
- NCT00106613
- Testing
- FK228 (romidepsin)
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Celgene
Renal Cell Cancer Metastatic
A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCC
This is a phase Ib,single arm,open label study evaluating the safety and efficacy of CT053PTSA in patients with advanced and metastatic renal cell cancer who have progressed from previous treatment
- Trial name
- NCT03876925
- Testing
- CT053PTSA
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Urothelial Carcinoma, Ureteral Neoplasms
TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma
Background: Urothelial cancer (tumors of the bladder, urethra, ureter, or renal pelvis) often responds initially to standard chemotherapy treatments, but frequently recurs and can often spread to other parts of the body.
- Conditions
- Urothelial Carcinoma, Ureteral Neoplasms, Ureter Cancer, Neoplasm, Ureteral
- Trial name
- NCT01328574
- Testing
- TRC105
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma
Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
This is a single-institution, phase 2 trial of zanzalintinib plus investigator-choice bone-strengthening agent in patients with metastatic renal cell carcinoma (RCC) with bone metastases whose disease has advanced on 1-3 prior…
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic, Clear Cell Renal Cancer
- Trial name
- ZAMBONI (NCT07043608)
- Testing
- Zanzalintinib, Investigator Choice of Bone Strengthening Agents (BSA), Non-Investigational Radiation Therapy (RT)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Kelly Fitzgerald, MD
Kidney Cancer, Renal Cell Cancer Metastatic
Prospective Evaluation of AI R&D Tool for Patient Stratification: a Trial for Renal Immuno-oncology Model Experimental Evaluation 2
Pear Bio has developed a predictive biomarker technology that combines 3D cell culture, microscopy and computer vision to measure the response of an individual patient's tumor sample to different systemic therapy regimens that…
- Trial name
- PEAR-TREE2 (NCT06264479)
- Testing
- Biopsy
- Where
- 4 sites in United Kingdom
- Volunteers
- 7 people
- Sponsor
- Ourotech, Inc.
Kidney Cancer
Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00073879
- Testing
- alemtuzumab, graft-versus-tumor induction therapy, cyclophosphamide
- Where
- United States
- Sponsor
- Baylor College of Medicine
Metastatic Renal Cell Carcinoma
Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy
The purpose of this retrospective observational study was to analyze the effect of targeted therapies administered as second-line treatment after failure of pazopanib as well as increase the amount of information available on…
- Trial name
- SPAZO (NCT02282579)
- Testing
- Pazopanib
- Where
- 34 sites in Spain
- Volunteers
- 300 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Metastatic Renal Cell Cancer, Malignant Melanoma, Metastatic
Radiotherapy As an Immunological Booster in Patients with Metastatic Melanoma or Renal Cell Carcinoma Treated with High-dose Interleukin-2
Title: Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with High-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response Phase: Proof of…
- Trial name
- IL2HD (NCT01884961)
- Testing
- Boost of radiotherapy + high dose IL-2 treatment
- Where
- Italy
- Volunteers
- 46 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Metastatic Renal Cell Carcinoma
Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma
Next-Generation Sequencing and whole transcriptome RNA sequencing were used to detect genomic variation and expression in tissues or blood, respectively.
- Trial name
- NCT05816642
- Testing
- sunitinib or pazopanib, PD-1 inhibitor combined with axitinib
- Where
- China
- Volunteers
- 500 people
- Sponsor
- RenJi Hospital
Metastatic Renal Cell Cancer
Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer
In the present phase 1-2 study the investigators aim to determine whether depletion of Tregs using metronomic cyclophosphamide can enhance the antitumor efficacy of everolimus in patients with mRCC not amenable to or progressive…
- Trial name
- NCT01462214
- Testing
- Everolimus
- Where
- 13 sites in Netherlands
- Volunteers
- 96 people
- Sponsor
- Hans J. van der Vliet, MD, PhD
Renal Cell Carcinoma (Kidney Cancer)
Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell
This study is being done to determine if the investigational radiotracer called 111In-XYIMSR-01 is helpful in detecting clear cell renal cell carcinoma tissue in your body when used during a SPECT-CT Scan
- Trial name
- NCT07062549
- Testing
- 111In-XYIMSR-01
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Kidney Cancer
Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells.
- Trial name
- NCT00003181
- Testing
- aldesleukin, sargramostim, vinblastine sulfate
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Hope Cancer Institute, Inc.
Renal Cell Carcinoma
A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
Renal cell carcinoma (RCC) accounts for more than 200,000 new cases of cancer and over 100,000 cancer deaths annually in the World (Ferlay, et al., 2004).
- Trial name
- NCT01206764
- Testing
- RAD001
- Where
- 22 sites in Algeria, Egypt and 8 more
- Volunteers
- 143 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Neoplasms
The Pharmacokinetic Variability of Sunitinib in Patients With Metastatic Renal Cancer
The primary objective of this study is to determine the percentage of patients with a plasma concentration of sunitinib remaining at equilibrium ([Suni]REq) greater than 100 ng / ml (effective concentration according to the…
- Trial name
- GenCInibs-Suni (NCT02404584)
- Testing
- Blood drawn for genotyping, Blood drawn for pharmacokinetic measures
- Where
- 3 sites in France
- Volunteers
- 43 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.